Skip to main content
. 2022 May 2;66(5):e00189-22. doi: 10.1128/aac.00189-22

TABLE 2.

Cross-susceptibility to ceftolozane-tazobactam, imipenem-relebactam, and ceftazidime-avibactam among P. aeruginosa isolates with different phenotypesa

Phenotype No. (% of all isolates) Antimicrobial agent, % susceptible
C/T IMR CZA
C/T-NS 90 (3.6) 0 52.2 38.9
IMR-NS 214 (8.5) 79.9 0 64.0
CZA-R 141 (5.6) 61.0 45.4 0
a

C/T, ceftolozane-tazobactam; IMR, imipenem-relebactam; CZA, ceftazidime-avibactam; NS, nonsusceptible; R, resistant.